Recursion acquires Vium for drug discovery

By The Science Advisory Board staff writers

July 28, 2020 -- Recursion has acquired Vium to advance its technologies and grow its drug discovery pipeline of over 30 programs.

Vium's platform combines computer vision, machine learning, and sensor technologies to noninvasively collect and derive insights from digital biomarkers in preclinical in vivo research. The acquisition will augment Recursion's in vitro datasets and bolster its core technologies.

Financial terms of the acquisition were not disclosed.

Copyright © 2020

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.